TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04723862
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
Study: NCT04723862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study: NCT06615284
Drug: Atorvo+™ (Arm1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
Study: NCT06615284
Drug: Atorvo+™ +CBD (Arm 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
Study: NCT06615284
Drug: Atorvo+™ +CBD (Arm 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
Study: NCT05397470
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered BID by mouth along with food.
Study: NCT06613698
Drug: GSK4532990
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4532990 will be administered
Study: NCT06613698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT05854992
Drug: Acute migraine treatment with any prescribed triptans
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
Study: NCT06683534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
Study: NCT06622499
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Study: NCT05901883
Drug: CEL383
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive CEL383
Study: NCT05901883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo
Study: NCT06631547
Drug: The usual head trauma care
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: the basic treatment
Study: NCT06628466
Drug: Nuberol Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of Life study
Study: NCT06690398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo administered orally once daily
Study: NCT04531397
Drug: ACEI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
Study: NCT04903808
Drug: Allium Sativum Oil
Normalized name: Allium sativum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic oil Captain Company (CAP-PHARM)
Study: NCT06697886
Drug: Antiwei Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
Study: NCT06697886
Drug: Antiwei Granules Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
Study: NCT04569227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO daily
Study: NCT06167707
Drug: SCP-111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
Study: NCT06574516
Drug: Ibuprofen 200 mg
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen every 8 hours for three days post operatively
Study: NCT06711562
Drug: Anti-Infective Drugs
Normalized name: INVESTIGATIONAL ANTI-INFECTIVE DRUGS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
Study: NCT05813717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06712771
Drug: VSA003
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injections
Study: NCT06712771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injections
Study: NCT04560569
Drug: 3BNC117 Antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
Study: NCT05120596
Drug: T3P-Y058-739 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05296629
Drug: DFD-29
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFD-29 (40 mg) extended release capsules
Study: NCT05296629
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 40 mg capsules
Study: NCT05296629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT05202379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT05925166
Drug: rhTNFR-Fc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
Study: NCT06710561
Drug: SPN01 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.
Study: NCT06710561
Drug: SPN01 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
Study: NCT04940390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for STS101
Study: NCT06450184
Drug: NUPLAZID 34 MG Oral Capsule
Normalized name: Nuplazid 34 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of Pimavanserin Capsule 34mg
Study: NCT04828694
Drug: BICX104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
Study: NCT05668091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.
Study: NCT05905458
Drug: HRS9950 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9950 tablets, oral, once a week, low dose
Study: NCT05905458
Drug: HRS9950 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9950 tablets, oral, once a week, high dose
Study: NCT05905458
Drug: HRS9950 placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9950 placebo tablets, oral, once a week.
Study: NCT05784987
Drug: X: Chidamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2\~4
Study: NCT04934228
Drug: Hydrochlorothiazide 12.5Mg Tab
Normalized name: HYDROCHLOROTHIAZIDE 12.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day
Study: NCT04934228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
Study: NCT06411145
Drug: OXERVATE® 0.002%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenegermin-bkbj (20 mcg/mL) is an ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 8-week course.
Study: NCT06476899
Drug: FCR/BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCR/BR
Study: NCT05247216
Drug: Hemay007 800 mg QD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
Study: NCT05247216
Drug: Hemay007 1200 mg QD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
Study: NCT05247216
Drug: Hemay007 600 mg QD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
Study: NCT05247216
Drug: Hemay007 placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
Study: NCT04955327
Drug: A. Paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract from A. Paniculata
Study: NCT04955327
Drug: A. Chilensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract from A. Chilensis
Study: NCT04955327
Drug: A. Paniculata and A. Chilensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of A. Paniculata and A. Chilensis
Study: NCT06245213
Drug: Placebo oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo comparator for the study.
Study: NCT05614895
Drug: RO7223280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
Study: NCT05614895
Drug: RO7223280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
Study: NCT05293236
Drug: ApTOLL
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
Study: NCT05951595
Drug: Artemether-Lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fixed-dose combination of AL will be used in the trial. Each paediatric (dispersible) or adult (non-dispersible) tablet will contain 20 mg artemether, 120 mg lumefantrine and will be administered in 6 doses over 3 days at H0, H8, H24, H36, H48 and H60. The target dosing will be in line with the ranges recommended by the WHO (total dose of 5-24 mg/kg of artemether, 29-144 mg/ kg of lumefantrine).
Study: NCT04720742
Drug: Analytical Treatment Interruption + bNAbs infusion
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
Study: NCT04835584
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Study: NCT04498715
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
Study: NCT00002184
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05824338
Drug: General anesthesia for lumbar surgery
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be intubated and ventilated under general anesthesia.
Study: NCT05814640
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commonly used oral antipsychotics intervention therapy.
Study: NCT06140966
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein: days 1-4 of each Induction cycle
Study: NCT05203055
Drug: Nucleotide Analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etecavir 0.5mg qd or Tenofovir 300mg qd
Study: NCT00043732
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05572333
Drug: EP395
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT05572333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT05394402
Drug: SHR0410 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0410 Injection
Study: NCT05394402
Drug: Placebo for SHR0410 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0410 Injection blank preparation
Study: NCT05226754
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
Study: NCT04774991
Drug: Azithromycin for Oral Suspension
Normalized name: Azithromycin for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin will be administered as a single dose in oral suspension form for children as follows:~* Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~* For children 1 to \<12 months of age, weight-based dosing will be used~* For children 12 to 59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.
Study: NCT05532254
Drug: Abilify® 10 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: an immediate-release tablet containing 10 mg Aripiprazole
Study: NCT05068388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05074498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT05070104
Drug: modified FFX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
Study: NCT05000450
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT05646511
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
Study: NCT05646511
Drug: CAPOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks, if the initial dose of irinotecan 150 mg/m²/day is tolerated, the dose can be increased to 200 mg/m²/day from the second cycle
Study: NCT05274984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group will be given the same volume of saline.
Study: NCT05062083
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 75 mg orally once
Study: NCT05062083
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 600 mg orally once
Study: NCT05665088
Drug: BXCL501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Film
Study: NCT05665088
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Placebo Film
Study: NCT05424003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution injected weekly for 72 weeks
Study: NCT05406752
Drug: paracetamol Uniflash (125 mg/ 1.25 mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oromucosal solution (125 mg/ 1.25 mL) for buccal route
Study: NCT05077865
Drug: MYMD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule
Study: NCT05077865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching in appearance to MyMD-1 150mg capsule
Study: NCT05373264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching oral capsule containing placebo
Study: NCT04606264
Drug: Neuraxial Analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
Study: NCT04606264
Drug: Regional Block 1: Paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
Study: NCT04606264
Drug: Regional Block 2: QL1
Approvals — FDA: no, EMA: no, PMDA: no
Description: This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
Study: NCT05173493
Drug: Tetracycline,Furazolidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline-Furazolidone-containing quadruple group
Study: NCT05383456
Drug: HIV Anti-retroviral Background Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study.
Study: NCT04905316
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
Study: NCT05324631
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302, oral, once daily
Study: NCT05324631
Drug: SHR0302 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 placebo, oral, once daily
Study: NCT05377619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
Study: NCT05118698
Drug: Gynostemma
Normalized name: GYNOSTEMMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
Study: NCT04780464
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
Study: NCT04780464
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
Study: NCT04780464
Drug: Cyclophosphamide Oral Product
Normalized name: cyclophosphamide Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BD on day 1 to day 7 of each 14 day cycle until PD
Study: NCT04780464
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD
Study: NCT05593627
Drug: Calcium Carbonate 500 MG Oral Tablet
Normalized name: Calcium Carbonate 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
Study: NCT05942547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily
Study: NCT03999840
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
Study: NCT04860141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
Study: NCT06447402
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of normal saline will be nebulised in the control arm
Study: NCT04660370
Drug: CKD-828, D097, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05968508
Drug: BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 150 subjects are planned to be enrolled and 1:1randomized to receive single dose of 162 mg/0.9 mL BAT1806 injection, or RoActemra® (from EU) subcutaneously.
Study: NCT04823520
Drug: TCA
Normalized name: RTCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive 6 sessions at 2 weeks intervals,the half face which will recieve MDA and TCA,MDA will be done before appling TCA.
Study: NCT05296564
Drug: CYCLOPHOSPHAMIDE and FLUDARABIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
Study: NCT05296564
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
Study: NCT04884399
Drug: CMAB818
Approvals — FDA: no, EMA: no, PMDA: no
Description: vascular endothelial growth factor (VEGF) inhibitor
Study: NCT04884399
Drug: Lucentis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: vascular endothelial growth factor (VEGF) inhibitor
Study: NCT06209359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.